Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (26)
Handy Riantana, Orawan Waenphimai, Panupong Mahalapbutr, Kun Karnchanapandh, Kulthida Vaeteewoottacharn, Sopit Wongkham & Kanlayanee Sawanyawisuth. (2023) BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines. Pathology - Research and Practice 248, pages 154678.
Crossref
Crossref
Zheng Zhou, Yusong Zhou, Wei Liu & Jing Dai. (2023) A novel cuproptosis-related lncRNAs signature predicts prognostic and immune of bladder urothelial carcinoma. Frontiers in Genetics 14.
Crossref
Crossref
Michela Chiappa, Serena Petrella, Giovanna Damia, Massimo Broggini, Federica Guffanti & Francesca Ricci. (2022) Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. Frontiers in Oncology 12.
Crossref
Crossref
Dandan Zhu, Jie Xia, Chao Liu & Chi Fang. (2022) Numb/Notch/PLK1 signaling pathway mediated hyperglycemic memory in pancreatic cancer cell radioresistance and the therapeutic effects of metformin. Cellular Signalling 93, pages 110268.
Crossref
Crossref
Nadia Halib, Nicola Pavan, Carlo Trombetta, Barbara Dapas, Rossella Farra, Bruna Scaggiante, Mario Grassi & Gabriele Grassi. (2022) An Overview of siRNA Delivery Strategies for Urological Cancers. Pharmaceutics 14:4, pages 718.
Crossref
Crossref
Tamires Cunha Almeida & Glenda Nicioli da Silva. (2021) Resveratrol effects in bladder cancer: A mini review. Genetics and Molecular Biology 44:1.
Crossref
Crossref
Celeste N. Alverez, Jung-Eun Park, Kiran S. Toti, Yangliu Xia, Kristopher W. Krausz, Ganesha Rai, Jeong K. Bang, Frank J. Gonzalez, Kenneth A. Jacobson & Kyung S. Lee. (2020) Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1. Journal of Medicinal Chemistry 63:22, pages 14087-14117.
Crossref
Crossref
Tatiane M. B. Barros, Ana P. B. Lima, Tamires C. Almeida & Glenda N. Silva. (2020) Inhibition of urinary bladder cancer cell proliferation by silibinin. Environmental and Molecular Mutagenesis 61:4, pages 445-455.
Crossref
Crossref
Jolien Van den Bossche, Andreas Domen, Marc Peeters, Christophe Deben, Ines De Pauw, Julie Jacobs, Sven De Bruycker, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Filip Lardon & An Wouters. (2019) Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status. Cancers 11:12, pages 1893.
Crossref
Crossref
Tamires Cunha Almeida, Camila Chaves Coelho Guerra, Bárbara Letícia Gonçalves De Assis, Rodrigo Dian Oliveira Aguiar Soares, Camila Carriao Machado Garcia, Angélica Alves Lima & Glenda Nicioli Silva. (2019)
Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different
TP53
status
. Environmental and Molecular Mutagenesis 60:8, pages 740-751.
Crossref
Crossref
Jolien Bossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Vanessa Deschoolmeester, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Baptist Vermorken, Marc Peeters, Filip Lardon & An Wouters. (2019)
In vitro
study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
. Molecular Oncology 13:5, pages 1196-1213.
Crossref
Crossref
Mengjiao Wu, Yan Wang, Di Yang, Ying Gong, Feng Rao, Rui Liu, Yeerken Danna, Jinting Li, Jiawen Fan, Jie Chen, Weimin Zhang & Qimin Zhan. (2019) A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. EBioMedicine 41, pages 244-255.
Crossref
Crossref
Ana C. Henriques, Diana Ribeiro, Joel Pedrosa, Bruno Sarmento, Patrícia M.A. Silva & Hassan Bousbaa. (2019) Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Cancer Letters 440-441, pages 64-81.
Crossref
Crossref
Chung-Pu Wu & Sheng-Chieh Hsu. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy
169
185
.
Zheng Fu & Donghua Wen. (2017) The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis. Cancers 9:12, pages 131.
Crossref
Crossref
Hironobu Yamashita, Vasty Osei Amponsa, Joshua I. Warrick, Zongyu Zheng, Peter E. Clark, Jay D. Raman, Xue-Ru Wu, Cathy Mendelsohn & David J. DeGraff. (2016) On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nature Reviews Urology 14:2, pages 98-106.
Crossref
Crossref
Kristian W Pajtler, Natalie Sadowski, Sandra Ackermann, Kristina Althoff, Kerstin Schönbeck, Katharina Batzke, Simonäfers Sch, Andrea Odersky, Lukas Heukamp, Kathy Astrahantseff, Annette Künkele, Hedwig E Deubzer, Alexander Schramm, Annikaüssel Spr, Theresa Thor, Sven Lindner, Angelika Eggert, Matthias Fischer & Johannes H Schulte. (2016) The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget 8:4, pages 6730-6741.
Crossref
Crossref
J.L. Chin, K.M. Siddiqui & K.-C. Tran. 2017. Introduction to Cancer Metastasis. Introduction to Cancer Metastasis
177
198
.
Rosie Elizabeth Ann Gutteridge, Mary Ann Ndiaye, Xiaoqi Liu & Nihal Ahmad. (2016) Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Molecular Cancer Therapeutics 15:7, pages 1427-1435.
Crossref
Crossref
J. Van den Bossche, F. Lardon, V. Deschoolmeester, I. De Pauw, J.B. Vermorken, P. Specenier, P. Pauwels, M. Peeters & A. Wouters. (2016) Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor. Medicinal Research Reviews 36:4, pages 749-786.
Crossref
Crossref
Kristin A. Greco, Carrie A. Franzen, Kimberly E. Foreman, Robert C. Flanigan, Paul C. Kuo & Gopal N. Gupta. (2016) PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. Urology 91, pages 241.e1-241.e7.
Crossref
Crossref
Chung-Pu Wu, Chia-Hung Hsieh, Sung-Han Hsiao, Shi-Yu Luo, Ching-Ya Su, Yan-Qing Li, Yang-Hui Huang, Chiun-Wei Huang & Sheng-Chieh Hsu. (2015) Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics 12:11, pages 3885-3895.
Crossref
Crossref
Rodrigo F.E. Bogado, Julia A. Pezuk, Harley F. de Oliveira, Luiz G. Tone & María S. Brassesco. (2015) BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. Anti-Cancer Drugs 26:1, pages 56-63.
Crossref
Crossref
Chung-Pu Wu, Sung-Han Hsiao, Shi-Yu Luo, Wei-Cherng Tuo, Ching-Ya Su, Yan-Qing Li, Yang-Hui Huang & Chia-Hung Hsieh. (2014) Overexpression of Human ABCB1 in Cancer Cells Leads to Reduced Activity of GSK461364, a Specific Inhibitor of Polo-like Kinase 1. Molecular Pharmaceutics 11:10, pages 3727-3736.
Crossref
Crossref
J.C. Oliveira, J.A. Pezuk, M.S. Brassesco, A.G. Morales, R.G.P. Queiroz, C.A. Scrideli & L.G. Tone. (2014)
PLK1
expression and BI 2536 effects in childhood acute lymphoblastic leukemia
. Pediatric Blood & Cancer 61:7, pages 1227-1231.
Crossref
Crossref
Sung-Han Hsiao, Shi-Yu Luo, Ching-Ya Su, Wei-Cherng Tuo, Cheng-Ting Chiang, Yan-Qing Li, Yang-Hui Huang & Chung-Pu Wu. (2014) The Overexpression of ABCG2 Reduces the Efficacy of Volasertib (BI 6727) and GSK641364 in Human S1-M1-80 Colon Carcinoma Cells. Journal of Cancer Research Updates 3:2.
Crossref
Crossref